Genscript Biotech Co. (OTCMKTS:GNNSF – Get Free Report) shares dropped 7.2% during mid-day trading on Thursday . The stock traded as low as C$1.60 and last traded at C$1.60. Approximately 500 shares traded hands during trading, a decline of 93% from the average daily volume of 7,031 shares. The stock had previously closed at C$1.73.
Genscript Biotech Stock Performance
The firm’s 50 day simple moving average is C$1.53 and its 200-day simple moving average is C$1.77.
About Genscript Biotech
GenScript Biotech Corporation is a global contract research, development and manufacturing organization (CDMO) specializing in synthetic biology and biopharmaceutical services. Founded in 2002, the company provides end-to-end solutions that span gene and peptide synthesis, recombinant protein expression, custom antibody discovery and cell line development. GenScript’s integrated platforms support early-stage discovery through to process development, enabling academic institutions, biotech innovators and pharmaceutical companies to accelerate research timelines.
The company’s core offerings include molecular biology services such as DNA construction, gene editing using CRISPR/Cas9 technology and high-throughput peptide libraries.
Featured Stories
- Five stocks we like better than Genscript Biotech
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for Genscript Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genscript Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
